Phase 1
N=56
Mood Effects of Serotonin Agonists Extended
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT03934710 ↗Enrolled (actual)
56
Serious AEs
0.0%
Results posted
Nov 2023
Primary outcome: Primary: DASS-21 — 2.9; 2.7; 4.5 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- Placebo (Drug); Serotonin agonist - 13ug (Drug); Serotonin agonist - 26ug (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Chicago
- Primary completion
- Jun 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY DASS-21 |
2.9; 2.7; 4.5 | — |
Summary
In this study we are examining the effects of repeated very low doses of serotonin agonists on mood individuals with negative mood.
Eligibility Criteria
Inclusion Criteria
- English fluency
- High school level education
- BMI between 19 and 30
Exclusion Criteria
- Diagnosed medical condition
- women who are nursing, pregnant, or plan to become pregnant within 3 months
- History of psychotic disorder or family history of psychotic disorder
Data sourced from ClinicalTrials.gov (NCT03934710). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.